Cell therapy manufacturing sales will expand through 2036, with commercial scale manufacturing at 58.0% of manufacturing scale demand and viral vector production at 32.0% of technology sales in 2026. The market was valued at USD 5.4 billion in 2025 and is forecast to record a 14.1% CAGR between 2026 and 2036.